Rxo (RXO) Equity Average (2021 - 2026)

Rxo (RXO) has reported Equity Average for 6 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.

• Equity Average for Q1 2026 came in at $1.5 billion, down 4.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 4.66% YoY), and the FY2025 annual result was $1.6 billion, up 42.93% from the prior year.
• Equity Average was $1.5 billion for Q1 2026 at Rxo, down from $1.6 billion in the prior quarter.
• Over five years, Equity Average peaked at $1.6 billion in Q4 2024 and troughed at $580.5 million in Q2 2024.
• Average Equity Average over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
• Year-over-year, Equity Average tumbled 49.68% in 2023 and soared 175.68% in 2024.
• Over 5 years, Equity Average stood at $865.5 million in 2022, then plunged by 31.6% to $592.0 million in 2023, then surged by 175.68% to $1.6 billion in 2024, then decreased by 4.38% to $1.6 billion in 2025, then dropped by 2.27% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Equity Average figures were $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.6 billion in Q3 2025.